Introduction - Alongside condom use, screening and treatment for bacterial sexually transmitted infections (STIs) are key strategic priorities in the fight against these infections. This article analyzes trends in STI screening in the private sector in France, based on individual healthcare reimbursement data from the French national health insurance system. Method - Health insurance reimbursement data provide information on the number of people screened for syphilis and infections caused by Chlamydia trachomatis or Neisseria gonorrhoeae in private laboratories (community laboratories and private healthcare facilities). National and regional screening rates were calculated per 1,000 people aged 15 and older, by age and sex. Trends were described starting in 2006, with a focus on the 2016–2018 period. Results - In 2018, 2.1 million people were tested for Chlamydia trachomatis infection, representing a rate of 39 per 1,000 inhabitants, an increase of 9% compared to 2016. Nearly 1.6 million people were screened for gonorrhea, representing a rate of 30 per 1,000, a sharp increase compared to 2016 (+18%). For these two infections, although rates are higher among those aged 25 and older, the increase in screening activity between 2016 and 2018 was twice as high among young people under 25 compared to those aged 25 and older, regardless of gender. The total number of people tested for syphilis was 1.8 million in 2018 (a rate of 33 per 1,000 inhabitants), a 7% decrease compared to 2016. This decrease, observed for the first time since 2006, applies only to women. Conclusion - The increase in screening for Chlamydia trachomatis and gonococcal infections from 2006 to 2018 among young people under 25 may result from greater awareness among the general public and healthcare professionals following prevention campaigns. In a context where surveillance data show that the number of diagnoses of these STIs continues to rise, it is essential to continue efforts to diversify screening services and target at-risk populations in order to bring the epidemics under control. The stability in syphilis testing activity, while testing for other bacterial STIs is increasing, will need to be confirmed in the coming years.